Trailing twelve months where a flow is involved, latest reported balance where it is not.
Both on one scale, because both are money — the bar that is taller is the one that matters.
Cash counts short-term investments, not just the bank balance — technology companies park most of it in marketable securities, and leaving those out understates it several times over. Debt includes lease obligations.
Not on the overview because five charts is as much as one decision needs — but here in full, on one period switch. Each quarter on its own, so seasonal highs and lows are visible.
-$28.12MQ3 2026
What was left after every cost, including tax. Each quarter on its own, so seasonal highs and lows are visible.
Everything above comes from ADARx Pharmaceuticals, Inc.’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted.
Not reported by this filer: Total Revenue, Cost of Revenue, Gross Profit, SG&A Expense, Total Operating Expenses, Profit Before Tax, Interest Expense, Income Tax Expense, Profit per share, Shares outstanding, Interest Income, Net Interest Income, Non-interest Income, Non-interest Expense, Provision for Credit Losses, Deposits, Loans, Shareholders Equity, Short-term Investments, Inventory, Receivables, Long-term Debt (noncurrent), Long-term Debt (current), Short-term Borrowings, Borrowings (total), Operating Lease (current), Operating Lease (noncurrent), Operating Lease (total), Finance Lease (current), Finance Lease Liabilities (total), Finance Lease (noncurrent), Operating Cash Flow, Capital Expenditures, Investing Cash Flow, Financing Cash Flow, Dividends paid, Impairments, Stock-Based Compensation, Depreciation & Amortization, Depreciation, Amortization of Intangibles, Share Repurchases, Change in Inventories, Change in Receivables, Change in Payables, Change in Payables and Accruals, Change in Customer Advances, Change in Other Operating Capital, Change in Working Capital, Accounts Payable, Acquisitions, and Shares Issued for Cash. Companies choose which XBRL tags to use, and anything untagged cannot be recovered — so these are blank rather than guessed.
ADRX · ·
$13.25-2.3%Nov 11 close
The latest quarter (ended September 30, 2026) is from ADARx Pharmaceuticals’s earnings press release of November 12, 2026. It will be replaced by the official quarterly report (10-Q) once ADARx Pharmaceuticals files it.